FindTrial
Sign In

Retrospective analysis for the hospital length of stay after lung lobectomy for lung cancer with sugammadex use as a reversal agent for neuromuscualrar blockade in general anesthesia

Hospital length of stay with sugammadex after open lobectomy for lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0004735
Enrollment
266
Registered
2020-02-13
Start date
2020-01-22
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Chonnam National University Hospital Hwasun Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients 19-yr of age or older who underwent elective open lobectomy for lung cancer from January 2010 to December 2015

Exclusion criteria

Exclusion criteria: Patients who underwent emergency surgery, underwent open lobectomy for other than lung neoplasm, paralyzed with neuromuscular blocker other than rocuronium,

Design outcomes

Primary

MeasureTime frame
hospital length of stay—

Secondary

MeasureTime frame
postoperative complication;5-years survival rate—

Countries

Korea, Republic of

Contacts

Public ContactJoungmin Kim

Chonnam National University Hospital

tca77@hanmail.net+82-62-220-6895

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 15, 2026